Drugs A-Z Is my price fair? Price changes Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme

Brand-name drug

Foundayo price, strengths & recalls

Brand of orforglipron (generic)

Pharmacies pay $627.48 for 30 tablets of Foundayo 0.8 mg tablet this week, and from $624.85 to $632.28 across its 6 priced strengths and forms. Its official label last changed on August 13, 2026.

Brand
Pharmacies pay$627.48for 30 tablets of 0.8 mg tablet+0.1% in 4 weeks
Fair cash price
$732.10
Strengths
6
Makers
1
Updated
Nov 11

Foundayo price by strength

What pharmacies pay for each strength and form this week (Nov 11, 2026), for 30 tablets. Choose one for its fair price, 52-week chart and makers.

Strength and formPer unitPharmacies pay4 weeks52 weeks
0.8 mg tablet Brand$20.92$627.48 / 30 tablets+0.1%
2.5 mg tablet Brand$20.89$626.78 / 30 tablets+0.3%
5.5 mg tablet Brand$20.88$626.34 / 30 tablets+0.3%
9 mg tablet Brand$20.92$627.49 / 30 tablets+0.3%
14.5 mg tablet Brand$20.83$624.85 / 30 tablets
17.2 mg tablet Brand$21.08$632.28 / 30 tablets

The lowest cost per tablet is 14.5 mg tablet at $20.83. Strengths aren't interchangeable - ask your pharmacist or prescriber before changing.

Foundayo vs generic orforglipron

There is no generic version of Foundayo on the market yet. Its last listed patent or exclusivity runs to September 26, 2037 - generics often follow, though court cases and settlements can move the date either way.

GenericOrforglipron prices

Supply status: shortages & recalls

No shortage reportedChecked Nov 15, 2026
No ongoing recallsNone on record

What did you pay for foundayo? Help the next person.

Every price shared helps the next person know what's fair - and shows which pharmacies charge the least. Anonymous, 30 seconds.

How were you treated? optional

Free, anonymous, no sign-up. Please don't include personal or health details. Community rules.

Official label & what changed

Last changedAugust 13, 2026
Version10 of 2
EffectiveJul 29, 2026
Read the label

These highlights do not include all the information needed to use FOUNDAYO safely and effectively. See full prescribing information for FOUNDAYO.FOUNDAYO (orforglipron) tablets, for oral useInitial U.S. Approval: 2026

This drug has a boxed warning

WARNING: RISK OF THYROID C-CELL TUMORS

In products with glucagon-like peptide-1 (GLP-1) receptor agonist activity that are pharmacologically active in rats and mice, rodent thyroid C-cell tumors (adenomas and carcinomas) have been observed at clinically relevant exposures and are considered GLP-1 receptor-dependent effects in rodents. Orforglipron is not pharmacologically active in rats or mice and did not produce tumors in rodents [see Nonclinical Toxicology (13.1)]. While orforglipron is pharmacologically active at the human GLP-1 receptor, the human relevance of GLP-1 receptor-dependent thyroid C-cell tumors observed in rodents has not been determined [see Warnings and Precautions (5.1), Nonclinical Toxicology (13.1)].

FOUNDAYO is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [see Contraindications (4)]. Counsel patients regarding the potential risk for MTC with the use of FOUNDAYO and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with FOUNDAYO [see Contraindications (4), Warnings and Precautions (5.1)].

WARNING: RISK OF THYROID C-CELL TUMORS

See full prescribing information for complete boxed warning.

In products with glucagon-like peptide-1 (GLP-1) receptor agonist activity that are pharmacologically active in rats and mice, rodent thyroid C-cell tumors (adenomas and carcinomas) have been observed at clinically relevant exposures and are considered GLP-1 receptor-dependent effects in rodents. Orforglipron is not pharmacologically active in rats or mice and did not produce tumors in rodents (13.1). While orforglipron is pharmacologically active at the human GLP-1 receptor, the human relevance of GLP-1 receptor-dependent thyroid C-cell tumors observed in rodents has not been determined (5.1, 13.1).

FOUNDAYO is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC and symptoms of thyroid tumors (4, 5.1).

We check this label every day. When it changes, the sections that changed appear here, old text beside new.

We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.

Approval, patents & generics

Application
NDA220934 · Eli Lilly And Co
First approved
April 1, 2026 (0 years ago)
Latest approved change
August 4, 2026
Approved label
PDF, Aug 4, 2026
Generic makers
None on the market
Last patent listed
September 26, 2037
Exclusivity ends
April 1, 2031

Patent dates are what the maker lists with FDA. Generic launch dates are often set by court rulings or settlements instead. Upcoming generics.

Foundayo questions

How much does foundayo cost without insurance?

Pharmacies pay about $627.48 for 30 tablets of foundayo 0.8 mg tablet ($20.92 per tablet). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $732.10. If you're quoted much more, check your quote and ask for the pharmacy's cash price.

Is there a generic for Foundayo?

Yes: orforglipron. Compare orforglipron prices.

Is foundayo in shortage?

No shortage is reported for foundayo right now. We check the national shortage list every day.

Has foundayo been recalled?

No recalls are on record for foundayo.

When did the foundayo label last change?

The official label was last updated on August 13, 2026 (version 10). See what changed.

Talk about foundayo

Be kind and stay on topic. No personal health details, links or selling. This is not medical advice.

No comments yet. Questions, tips, what worked for you - start the conversation.

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.